
Loncar Cancer Immunotherapy ETF (Fri, May 03, 2024)

Buy candidate since May 03, 2024

StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania





Frend:	Sell
MV Long:	Buy
MV Short:	Buy
Pivot:	Buy
Volume:	Sell
MACD:	Buy

Tech commentaries:

The Loncar Cancer Immunotherapy ETF price gained 2.79% on the last trading day (Friday, 3rd May 2024), rising from \$15.43 to \$15.86. During the last trading day the ETF fluctuated 1.27% from a day low at \$15.70 to a day high of \$15.90. The price has risen in 6 of the last 10 days and is up by 12.4% over the past 2 weeks. Volume fell on the last day by -5 thousand shares and in total, 6 thousand shares were bought and sold for approximately \$94.32 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The ETF lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the ETF is expected to fall **-8.15%** during the next 3 months and, with a 90% probability hold a price between **\$12.68** and **\$15.42** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

The Loncar Cancer Immunotherapy ETF holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the ETF has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at \$14.98 and \$15.43. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Thursday, April 25, 2024, and so far it has risen 13.69%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. Volume fell during the last trading day while the price increases. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Loncar Cancer Immunotherapy finds support from accumulated volume at \$15.66 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the ETF meets some resistance just above today's level from accumulated volume at **\$16.26**, **\$16.75** and **\$16.80**.

This ETF has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the ETF moved **\$0.200** between high and low, or **1.27%**. For the last week the ETF has had daily average volatility of **3.23%**

Several short-term signals are positive, despite the ETF being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for ETF to perform well in the short-term. We have upgraded our analysis conclusion for this ETF since the last evaluation from a Hold/Accumulate to a Buy candidate.

Risk: Medium

Evoluction: Duy Condidate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.